Media & PR
Dr Reinhard Malin
Binger Strasse 173
55216 Ingelheim am Rhein
For Media outside the U.S. and Canada
Ingelheim, Germany, January 21, 2011 - The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate,1 Boehringer Ingelheim’s novel, oral direct thrombin inhibitor2 under the brand name Prazaxa®* for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.
Prazaxa® will be available to the approximately 830,000 AF patients at risk of stroke in Japan,3 with 150 mg bid (given as 2 capsules of 75 mg) recommended as the standard dose and 110 mg bid available for specific patient types considered to be at a higher risk of bleeding. The approval is based on findings from RE-LY®, the largest AF trial completed to date. In RE-LY®, dabigatran etexilate 150 mg bid significantly reduced the risk of stroke and systemic embolism by 35 percent beyond the reduction achieved with well controlled warfarin (median TTR 67 %),4 the long-time standard of care, in addition to reductions in life-threatening and intracranial bleeding.5,6 Dabigatran etexilate is the only novel oral anticoagulant proven to be superior to warfarin and was recently approved in the U.S. and Canada.7,8
Dr. Stuart Connolly, co-principal investigator of RE-LY®, Director, Division of Cardiology at McMaster University and member of The Population Health Research Institute, Hamilton, Ontario said, "Until today, physicians in Japan have had little choice but to use warfarin, which imposes challenging restrictions on people’s quality of life. Besides being a safe and more effective alternative to warfarin, dabigatran etexilate does not require monitoring, dose adjustments and is not affected by food, which truly is a huge shift in the treatment of stroke prevention in AF."
The approval of Prazaxa® is one of the fastest ever undertaken by the Japanese Ministry of Health, Labour and Welfare with authorisation of the novel agent gained 10 months after the filing of a new drug application. The speed of the approval underlines the current unmet need in stroke prevention in AF in Japan and the strength of data supporting dabigatran etexilate in this indication.
Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim said, "The approval of dabigatran etexilate for stroke prevention in AF in Japan is a very important step towards our goal to make this treatment available to all patients with AF at risk of stroke. It is a milestone as it marks the first approval of a novel oral anticoagulant in the Asia-Pacific region in nearly 50 years. We look forward to working with regulatory authorities worldwide regarding the approval of this breakthrough therapy."
About dabigatran etexilate
Dabigatran etexilate is at the forefront of a new generation of oral anticoagulants/direct thrombin inhibitors (DTIs)2 targeting a high unmet medical need in the prevention and treatment of acute and chronic thromboembolic diseases.
Potent antithrombotic effects are achieved with direct thrombin inhibitors by specifically blocking the activity of thrombin (both free and clot-bound), the central enzyme in the process responsible for clot (thrombus) formation. In contrast to vitamin-K antagonists, which variably act via different coagulation factors, dabigatran etexilate provides effective, predictable and consistent anticoagulation with a low potential for drug-drug interactions and no drug-food interactions, without the need for routine coagulation monitoring or dose adjustment.
Dabigatran etexilate has already been approved in 75 countries under the trademark Pradaxa® (in Canada: Pradax®) for the primary prevention of venous thromboembolic events (blood clots) in adults who have undergone elective total hip or elective total knee replacement surgery.
Dabigatran etexilate is only approved for clinical use in stroke risk reduction in non-valvular atrial fibrillation prevention in the US and the prevention of stroke, and systemic embolism in adults with atrial fibrillation in Canada. This information is provided for medical education purposes only.
About the dabigatran etexilate clinical trial programme
Boehringer Ingelheim’s clinical trial program to evaluate the efficacy and safety of dabigatran etexilate encompasses studies in:
RE-LY® (Randomized Evaluation of Long term anticoagulant therapY) was a global, phase III, randomised trial of 18,113 patients enrolled in over 900 centres in 44 countries, investigating whether dabigatran etexilate (2 blinded doses) is as effective as well controlled warfarin with target INR of 2.0-3.0 for stroke prevention. Patients were followed-up in the study for a median of 2 years with a minimum of 1 year follow-up.5,6
The primary endpoint of the trial was incidence of stroke (including haemorrhagic) or systemic embolism. Secondary outcome measures included all-cause death, incidence of stroke (including haemorrhagic), systemic embolism, pulmonary embolism, acute myocardial infarction, and vascular death (including death from bleeding).
Compared to well controlled warfarin, dabigatran etexilate showed in the trial.5,6
About AF and stroke
AF is the most common heart rhythm condition,9 affecting nearly one in four people over the age of 4010 and 1 % of the total population, rising to 10 % in people over the age of 80.11 People with AF are more likely to experience blood clots, which increases the risk of stroke by five-fold.12,13 Up to three million people worldwide suffer strokes related to AF each year,14-17 which are typically severe and disabling, with one half of this population dying within one year.17 Strokes due to AF tend to be severe, with an increased likelihood of death (20 %), and disability (60 %). Many AF-related strokes can be prevented with appropriate antithrombotic therapy.18
Boehringer Ingelheim - The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 Years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the USA or Canada.
|page||01 June 2012 1 Mission 1 Million|
|page||01 November 2011 Dabigatran|
|page||01 September 2014 Dabigatran etexilate|
1Prazaxa® product information, January 2011
2Di Nisio M, et al. Direct Thrombin Inhibitors. N Engl J Med 2005; 353:1028-40
3Inoue H, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. International Journal of Cardiology 2009; 137:102–107.
4FDA Advisory Committee Briefing Document, September 2010, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf
5Connolly SJ, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361:1139-51.
6Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L: Newly identified events in the RE-LY® trial. N Engl J Med 2010; 363(19): 1875-1876 (November 4th, 2010)
7U.S. Food and Drug Administration – Pradaxa® Prescribing Information. Oct 19th, 2010
8Health Canada – PRADAX™ Prescribing Information. Oct 26th, 2010.
9Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90:286-92
10Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation. Circulation 2004;110:1042-6
11Stewart S, Murphy N, Walker A, et al. Cost of an Emerging Epidemic: an Economic Analysis of Atrial Fibrillation in the UK. Heart 2004; 90:286-92.
12Fuster V, Rydn LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation – executive summary. Circulation 2006; 114:700-52.
13Kannel WB, et al. Final Draft Status of the Epidemiology of Atrial Fibrillation. Med Clin North Am. 2008; 92(1): 17–ix.
14Atlas of Heart Disease and Stroke, World Health Organization, September 2004. Viewed July 2009 at http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf.
15Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991: 22(8);983-8.
16Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischaemic stroke: results from a population-based study. Stroke 2005; 36:1115-9.
17Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996; 27:1760-4.
18Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501
*Approved under the brand name Pradaxa® in Europe for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or elective total knee replacement surgery and in the USA for for stroke risk reduction in patients with non-valvular atrial fibrillation.